AllianceBernstein’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

AllianceBernstein’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,189	Closed	-$2.02M	–	3003
2015 Q2	$2.02M	Buy	3,189 +1,041	+48%	+$553K	﹤0.01%	1799
2015 Q1	$1.1M	Buy	2,148 +2,093	+3,805%	+$1.06M	﹤0.01%	2133
2014 Q4	$30K	Sell	55 -20	-27%	-$9.01K	﹤0.01%	3177
2014 Q3	$112K	Buy	75 +36	+92%	+$52.1K	﹤0.01%	2942
2014 Q2	$53K	Buy	39 +36	+1,200%	+$41.8K	﹤0.01%	3106
2014 Q1	$4K	Sell	3 -83	-97%	-$96.5K	﹤0.01%	3353
2013 Q4	$85K	Sell	86 -24	-22%	-$24.8K	﹤0.01%	2949
2013 Q3	$115K	Sell	110 -29	-21%	-$31K	﹤0.01%	2967
2013 Q2	$152K	Buy	+139	New	+$155K	﹤0.01%	2898

Other funds holding VIRX

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein's VIRX Position: Q3 2015 in Review

AllianceBernstein sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 3,189 shares — an estimated $2.02M sold.

AllianceBernstein first reported a position in VIRX in Q2 2013 and held it in 9 quarters. The position peaked at $2.02M in Q2 2015. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

AllianceBernstein reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
AllianceBernstein sold 3,189 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $2.02M.
AllianceBernstein first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
AllianceBernstein's Viracta Therapeutics, Inc. Common Stock position peaked at $2.02M in Q2 2015.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on AllianceBernstein's 13F filing for Q3 2015, filed 13 Nov 2015.